Log in

CVE:SVSSolarvest Bioenergy Stock Price, Forecast & News

+0.01 (+9.52 %)
(As of 05/29/2020 04:00 PM ET)
Today's Range
Now: C$0.12
50-Day Range
MA: C$0.09
52-Week Range
Now: C$0.12
Volume15,000 shs
Average Volume29,139 shs
Market CapitalizationC$4.52 million
P/E RatioN/A
Dividend YieldN/A
Solarvest BioEnergy Inc. engages in the development of algal-based production systems to produce natural based green commercial products in Canada and internationally. Its algal-based production systems are used to produce nutritional nutraceuticals, pharmaceutical oils, and biologic active ingredients/therapies. The company is developing algae strains for the food enhancement and nutraceutical markets; and producing proteins as a therapeutic. It has a collaborative research and development agreement with FSD Pharma Inc. to develop algae-based pharma-grade cannabinoids. Solarvest BioEnergy Inc. was incorporated in 2005 and is based in Vancouver, Canada.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.18 out of 5 stars

Industry, Sector and Symbol

Industry Conglomerates



Sales & Book Value

Annual SalesN/A
Cash FlowC$0.06 per share
Book ValueC($0.06) per share



Market CapC$4.52 million
Next Earnings DateN/A
OptionableNot Optionable

Receive SVS News and Ratings via Email

Sign-up to receive the latest news and ratings for SVS and its competitors with MarketBeat's FREE daily newsletter.

Solarvest Bioenergy (CVE:SVS) Frequently Asked Questions

How has Solarvest Bioenergy's stock been impacted by COVID-19 (Coronavirus)?

Solarvest Bioenergy's stock was trading at C$0.08 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, SVS shares have increased by 43.8% and is now trading at C$0.12. View which stocks have been most impacted by Coronavirus.

Has Solarvest Bioenergy been receiving favorable news coverage?

News coverage about SVS stock has trended very negative on Sunday, InfoTrie Sentiment reports. The research group ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Solarvest Bioenergy earned a media sentiment score of -3.5 on InfoTrie's scale. They also gave headlines about the company a news buzz of 9.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the near term. View the latest news aboutSolarvest Bioenergy.

Who are some of Solarvest Bioenergy's key competitors?

Who are Solarvest Bioenergy's key executives?

Solarvest Bioenergy's management team includes the following people:
  • Mr. Kenneth Anthony Cawkell B.A., LL.B., Chairman & Corp. Sec. (Age 68)
  • Mr. Gerri J. Greenham, Pres, CEO & Director (Age 68)
  • Mr. Ching-Hiang Heng, Chief Financial Officer (Age 73)
  • Mr. Garth Greenham, Chief Operating Officer

What is Solarvest Bioenergy's stock symbol?

Solarvest Bioenergy trades on the Canadian Venture Exchange (CVE) under the ticker symbol "SVS."

How do I buy shares of Solarvest Bioenergy?

Shares of SVS and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab.

What is Solarvest Bioenergy's stock price today?

One share of SVS stock can currently be purchased for approximately C$0.12.

How big of a company is Solarvest Bioenergy?

Solarvest Bioenergy has a market capitalization of C$4.52 million.

What is Solarvest Bioenergy's official website?

The official website for Solarvest Bioenergy is www.solarvest.ca.

How can I contact Solarvest Bioenergy?

Solarvest Bioenergy's mailing address is 439 Helmcken St, VANCOUVER, BC V6B 2E6, Canada. The company can be reached via phone at +1-604-6843323.

This page was last updated on 5/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.